Research Papers

25 of 710 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Regulation of the hippocampal translatome by Apoer2-ICD release.
Wasser CR; Werthmann GC; Hall EM; Kuhbandner K; Wong CH; Durakoglugil MS; Herz J.
Mol Neurodegener (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Current views on meningeal lymphatics and immunity in aging and Alzheimer's disease.
Rego S; Sanchez G; Da Mesquita S.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function.
Jiao HS; Yuan P; Yu JT.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral i…
Ismail Z; Leon R; Creese B; Ballard C; Robert P; Smith EE.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
ACSS2-dependent histone acetylation improves cognition in mouse model of Alzheimer's disease.
Lin Y; Lin A; Cai L; Huang W; Yan S; Wei Y; Ruan X; Fang W; Dai X; Cheng J; Zhang J; Chen W; Ye Q; Chen X; Zhang J.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease.
Inoue Y; Shue F; Bu G; Kanekiyo T.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The gut microbiome regulates astrocyte reaction to Aβ amyloidosis through microglial dependent and independent mechanis…
Chandra S; Di Meco A; Dodiya HB; Popovic J; Cuddy LK; Weigle IQ; Zhang X; Sadleir K; Sisodia SS; Vassar R.
Mol Neurodegener (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Park…
Singh Y; Trautwein C; Romani J; Salker MS; Neckel PH; Fraccaroli I; Abeditashi M; Woerner N; Admard J; Dhariwal A; Dueholm MKD; Schäfer KH; Lang F; Otzen DE; Lashuel HA; Riess O; Casadei N.
Mol Neurodegener (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic st…
Yu SP; Jiang MQ; Shim SS; Pourkhodadad S; Wei L.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients.
Ramanan VK; Day GS.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeted degradation of ⍺-synuclein aggregates in Parkinson's disease using the AUTOTAC technology.
Lee J; Sung KW; Bae EJ; Yoon D; Kim D; Lee JS; Park DH; Park DY; Mun SR; Kwon SC; Kim HY; Min JO; Lee SJ; Suh YH; Kwon YT.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores.
Kang M; Ang TFA; Devine SA; Sherva R; Mukherjee S; Trittschuh EH; Gibbons LE; Scollard P; Lee M; Choi SE; Klinedinst B; Nakano C; Dumitrescu LC; Durant A; Hohman TJ; Cuccaro ML; Saykin AJ; Kukull WA; Bennett DA; Wang LS; Mayeux RP; Haines JL; Pericak-Vance MA; Schellenberg GD; Crane PK; Au R; Lunetta KL; Mez JB; Farrer LA.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer's Disease drug candidate.
Nemergut M; Marques SM; Uhrik L; Vanova T; Nezvedova M; Gadara DC; Jha D; Tulis J; Novakova V; Planas-Iglesias J; Kunka A; Legrand A; Hribkova H; Pospisilova V; Sedmik J; Raska J; Prokop Z; Damborsky J; Bohaciakova D; Spacil Z; Hernychova L; Bednar D; Marek M.
Mol Neurodegener (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
The role of peripheral inflammatory insults in Alzheimer's disease: a review and research roadmap.
Walker KA; Le Page LM; Terrando N; Duggan MR; Heneka MT; Bettcher BM.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Looking for answers far away from the soma-the (un)known axonal functions of TDP-43, and their contribution to early NM…
Ionescu A; Altman T; Perlson E.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Neuropathology of incidental Lewy body & prodromal Parkinson's disease.
Koeglsperger T; Rumpf SL; Schließer P; Struebing FL; Brendel M; Levin J; Trenkwalder C; Höglinger GU; Herms J.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer's disease: an updated …
Formolo DA; Yu J; Lin K; Tsang HWH; Ou H; Kranz GS; Yau SY.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Carriers of the p.P522R variant in PLCγ2 have a slightly more responsive immune system.
Diks AM; Teodosio C; de Mooij B; Groenland RJ; Naber BAE; de Laat IF; Vloemans SA; Rohde S; de Jonge MI; Lorenz L; Horsten D; van Dongen JJM; Berkowska MA; Holstege H.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeting a vulnerable septum-hippocampus cholinergic circuit in a critical time window ameliorates tau-impaired memory…
Wu D; Yu N; Gao Y; Xiong R; Liu L; Lei H; Jin S; Liu J; Liu Y; Xie J; Liu E; Zhou Q; Liu Y; Li S; Wei L; Lv J; Yu H; Zeng W; Zhou Q; Xu F; Luo MH; Zhang Y; Yang Y; Wang JZ.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplifi…
Bellomo G; Paciotti S; Concha-Marambio L; Rizzo D; Wojdaƚa AL; Chiasserini D; Gatticchi L; Cerofolini L; Giuntini S; De Luca CMG; Ma Y; Farris CM; Pieraccini G; Bologna S; Filidei M; Ravera E; Lelli M; Moda F; Fragai M; Parnetti L; Luchinat C.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications.
Gonzalez-Ortiz F; Kac PR; Brum WS; Zetterberg H; Blennow K; Karikari TK.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy.
Xiong M; Wang C; Gratuze M; Saadi F; Bao X; Bosch ME; Lee C; Jiang H; Serrano JR; Gonzales ER; Kipnis M; Holtzman DM.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130.
Müller SA; Shmueli MD; Feng X; Tüshaus J; Schumacher N; Clark R; Smith BE; Chi A; Rose-John S; Kennedy ME; Lichtenthaler SF.
Mol Neurodegener (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Translational molecular imaging and drug development in Parkinson's disease.
Haider A; Elghazawy NH; Dawoud A; Gebhard C; Wichmann T; Sippl W; Hoener M; Arenas E; Liang SH.
Mol Neurodegener (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Common mouse models of tauopathy reflect early but not late human disease.
Wenger K; Viode A; Schlaffner CN; van Zalm P; Cheng L; Dellovade T; Langlois X; Bannon A; Chang R; Connors TR; Oakley D; Renard B; Rappsilber J; Hyman B; Steen H; Steen JA.
Mol Neurodegener (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared